Key result
TEER and TTVR improved NYHA class (RR 1.46 and 3.28) vs medical therapy but did not reduce mortality (RR 0.99 and 0.85) and increased major bleeding (NNH 29 and 21).
Why the study?
Does transcatheter edge-to-edge repair (TEER) or transcatheter tricuspid valve replacement (TTVR) improve outcomes in patients with symptomatic moderate-to-severe tricuspid regurgitation compared to optimal medical therapy?
Meta-Analysis (n=1,050)
Does transcatheter edge-to-edge repair (TEER) or transcatheter tricuspid valve replacement (TTVR) improve outcomes in patients with symptomatic moderate-to-severe tricuspid regurgitation compared to optimal medical therapy?
Relative Risk: 0.99 (95% CI 0.56–1.76)
In patients with symptomatic moderate-to-severe tricuspid regurgitation, TEER and TTVR provide clinically meaningful improvements in functional status and quality of life compared to medical therapy, though they do not reduce mortality and carry increased risks of bleeding and pacemaker implantation.
No takes yet. Share an insight, caveat, or question.
TEER/TTVR may be considered for symptom relief in tricuspid regurgitation despite risks; reinforces lack of mortality benefit in Level-1 evidence.
Veettil et al. (2026) conducted a meta-analysis in Moderate-to-severe tricuspid regurgitation (n=1,050). Transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve replacement (TTVR) vs. Optimal medical therapy (OMT) was evaluated on All-cause mortality (TEER vs OMT) (RR 0.99, 95% CI 0.56-1.76). TEER and TTVR improved NYHA class (RR 1.46 and 3.28) vs medical therapy but did not reduce mortality (RR 0.99 and 0.85) and increased major bleeding (NNH 29 and 21).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: